Tologar Joan KM

MEMORANDUM

To:

Ian Franklin

Angus McMillan Douglas

Tony Napier Gail Williams Maurice McClelland

cc:

From: Date:

Dr Angela Robinson 29 October 1997

Subject:

CID

PRIVATE & CONFIDENTIAL

At the last MSBT meeting, 27th October 1997, I was made aware of the following new CPMP Guidance to minimise the risk of transmission of nv-CJD via plasma derived medicinal products, which was in fact a UK recommendation.

CPMP have agreed the following recommendation (MCA notified 23/10/97) -

"There should be a recall of batches of blood products if a blood donation to a plasma pool was subsequently found to have been made from a person who developed nv-CJD".

I need to inform you that such a recall will be taking place tomorrow as we have identified that plasma from an individual who subsequently developed nv-CJD entered a BPL plasma pool in 1995. Albumin and factor VIII prepared from this pool are still in date and therefore 10 3000 we could have recal etter. - ebold - BPI MCA have instructed BPL to undertake a recall.

I will ensure that you received copies of a pre-prepared press statement and a Q & A brief as soon as they are organised but felt I should give you early warning of this situation and also make you aware of this new agreed CPMP guidance which means that as Transfusion Services the onus is on us to establish whether or not cases of nv-CJD have given previous donations and to actively trace the fate of those donations.

GRO-C

GRO-C

National Blood Authority, Oak House, Reeds Crescent Watford, Herts WD1 1QH